MedPath

Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma

Not Applicable
Recruiting
Conditions
Neoplasms
Registration Number
KCT0002932
Lead Sponsor
Samsung Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
240
Inclusion Criteria

1. Age = 19 years and < 80 years
2. Histologically confirmed squamous cell carcinoma of the esophagus
3. Participants underwent endoscopic submucosal dissection for clinical stage as cT1N0M0 (AJCC/UICC 7th Edition) esophageal cancer according to upper GI endoscopy or endoscopic ultrasound and chest computed tomography (CT) scans
4. Pathologic examination after endoscopic submucosal dissection confirmed the presence of submucosal invasion (pathologic T1b) or lymphovascular invasion
5. For participants with multiple lesions, all of them should be resected with endoscopic submucosal dissection and at least one lesion should have pathologic submucosal invasion (pT1b) or lymphovascular invasion
6. articipants should agree to participate in the study and sign the informed consent form

Exclusion Criteria

1. Cervical esophageal cancer (proximal to 20cm from incisor teeth)
2. Regional lymph node metastasis (cN+) or distant metastasis (cM1) are suspected or confirmed on chest CT scans or positron emission tomography (PET)/CT scans
3. Recurrent esophageal cancer
4. Uncontrolled systemic disease which makes participants medically unfit for additional treatment (esophagectomy or concurrent chemoradiotherapy) such as congestive heart failure, interstitial lung disease, severe pulmonary emphysema or chronic renal failure
5. Gastric conduit is not available for esophageal reconstruction (ex.: previous history of gastrectomy)
6. Synchronous or metachronous multiple cancers (within the past 3 years) with the exclusion of skin cancer, well differentiated thyroid cancer, early gastric cancer achieving curative endoscopic resection, low grade prostate cancer (Gleason Score=6) )

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
3-year overall survival status
Secondary Outcome Measures
NameTimeMethod
Overall survival;Disease-free survival;Quality of life (Esophageal Cancer patient-specific);Gastrointestinal symptoms;Depression;Sleep disorder;Quality of life (Fatigue);Treatment-related complications or adverse events;Pulmonary function
© Copyright 2025. All Rights Reserved by MedPath